Download Files:
Products Details
Product Description
– Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.
Web ID
– HY-50101
Storage Temperature
– 4°C (Powder, stored under nitrogen)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C21H27N5
Citations
– Br J Haematol. 2022 Dec 19.|Patent. US20220273751A1.|PLoS One. 2016 Mar 21;11(3):e0151765.|Oncol Rep. 2022 Apr;47(4):68.
References
– [1]Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308.|[2]Chow LN, et al. Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice. PLoS One. 2016 Mar 21;11(3):e0151765.|[3]Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88.
CAS Number
– 558447-26-0
Molecular Weight
– 349.47
Compound Purity
– 95.0
SMILES
– NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@@H]3C4=C(CCC3)C=CC=N4
Clinical Information
– Phase 3
Research Area
– Infection; Endocrinology; Cancer
Solubility
– 10 mM in DMSO
Target
– CXCR;HIV
Isoform
– CXCR4;HIV-1
Pathway
– Anti-infection;GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
